Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Nov 27, 2020 11:03am
127 Views
Post# 31988875

RE:RE:RE:RE:3 Q financials out

RE:RE:RE:RE:3 Q financials outFrom a revenue standpoint and net profit, yes...some have thought that a front heavy H1 with 40% rev growth would hurt H2. A lot of companies would love to see 20% rev growth during this global pandemic.

Q3 shows rev up 20% and a turnaround of over $300K.  Also consider current vs. last years Q, R&D up $170K as well.


Stocker46 wrote: A Net Profit of less than $.2 m can hardly be considered a strong quarter.

More promises but it's doubful much will happen over the next several months. I'll consider selling all or a portion of my shares because there's little doubt the SP will drop from here .. if it gets low enough, I'll consider whether or not to get back in.





<< Previous
Bullboard Posts
Next >>